Myasthenia Gravis (MG) Treatment Industry Forecast to 2030: A $2.5 Billion Market Dominated by Alexion Pharma, Grifols, Avadel Pharma, Novartis, Pfizer, AbbVie, and Roche
17 avr. 2024 04h05 HE
|
Research and Markets
Dublin, April 17, 2024 (GLOBE NEWSWIRE) -- The "Myasthenia Gravis Treatment Market Report: Trends, Forecast and Competitive Analysis to 2030" report has been added to ResearchAndMarkets.com's...
NMD Pharma Receives FDA IND Clearance to initiate a Phase 2b Clinical Trial of NMD670 in Generalized Myasthenia Gravis Patients in the US
22 mars 2024 07h00 HE
|
NMD Pharma
NMD Pharma Receives FDA IND Clearance to initiate a Phase 2b Clinical Trial of NMD670 in Generalized Myasthenia Gravis Patients in the US Aarhus, Denmark, 22 March 2024 – NMD Pharma A/S, a...
NMD Pharma Receives FDA IND Clearance to initiate a Phase 2b Clinical Trial of NMD670 in Generalized Myasthenia Gravis Patients in the US
22 mars 2024 02h00 HE
|
NMD Pharma
NMD Pharma Receives FDA IND Clearance to initiate a Phase 2b Clinical Trial of NMD670 in Generalized Myasthenia Gravis Patients in the US Aarhus, Denmark, 22 March 2024 – NMD Pharma A/S, a...
NMD Pharma Publishes Comprehensive Data Package for NMD670 in Science Translational Medicine
21 mars 2024 07h00 HE
|
NMD Pharma
NMD Pharma Publishes Comprehensive Data Package for NMD670 in Science Translational Medicine ClC-1 is a chloride ion channel specifically expressed in skeletal muscle cells that normally dampens...
NMD Pharma Publishes Comprehensive Data Package for NMD670 in Science Translational Medicine
21 mars 2024 02h00 HE
|
NMD Pharma
NMD Pharma Publishes Comprehensive Data Package for NMD670 in Science Translational Medicine ClC-1 is a chloride ion channel specifically expressed in skeletal muscle cells that normally dampens...
Myasthenia Gravis Treatment Market Will Experience Growth, Reaching US$4.1 Billion by the End of 2030, Predicts Persistence Market Research
23 janv. 2024 01h45 HE
|
Persistence Market Research
New York, Jan. 23, 2024 (GLOBE NEWSWIRE) -- Myasthenia Gravis Treatment Market Poised for Steady Growth, driven by Innovation and Rising Awareness The global market for myasthenia gravis (MG)...
Global Myasthenia Gravis Treatment Market Forecast and Trends 2023-2028, Featuring Profiles of AbbVie, Bausch Health, Gilead Sciences, Merck, Servier and Teva
18 déc. 2023 06h43 HE
|
Research and Markets
Dublin, Dec. 18, 2023 (GLOBE NEWSWIRE) -- The "Global Myasthenia Gravis Treatment Market: Forecast and Trends" report has been added to ResearchAndMarkets.com's offering. The global market for...
Myasthenia Gravis Treatment Market Size, Share & Growth Analysis, [2028] | With CAGR of 7.5%
06 déc. 2023 07h28 HE
|
Fortune Business Insights
Pune, India, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Global Myasthenia Gravis Treatment Market Size was valued at USD 1.15 billion in 2020 and is projected to grow from USD 2.03 billion by 2028 exhibiting...
Catalyst Pharmaceuticals Receives Two New U.S. Patent Allowances For FIRDAPSE®
02 nov. 2023 10h37 HE
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing,...
Myasthenia Gravis Market is Projected to Boost at a Moderate Growth Rate by 2032, Estimates DelveInsight | Leading Companies - DAS-MG, Catalyst, Cabaletta Bio, Janssen, Argenx, UCB Pharma, Alexion, Immunovant
25 oct. 2023 13h00 HE
|
DelveInsight Business Research LLP
New York, USA, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Myasthenia Gravis Market is Projected to Boost at a Moderate Growth Rate by 2032, Estimates DelveInsight | Leading Companies - DAS-MG, Catalyst,...